Key Drivers
- Strong FCF
- Very high gross-margin
- Significant net-leverage
AIAI Summary
Jazz has shifted from a single‑franchise cash story into a hybrid high‑margin neuroscience/CBD cash engine plus an emerging oncology growth pivot, meaning valuation now hinges less on oxybate risk and more on zanidatamab regulatory/early commercial execution and sustained Xywav uptake. Track the RTOR sBLA timing, early Ziihera launch metrics, and FCF allocation to debt reduction—success will re‑rate the stock, while oncology failure or rapid oxybate erosion would likely trigger impairments and sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •Very high gross-margin
- •Significant net-leverage
Jazz generates strong free cash flow and very high gross margins with a profitable latest quarter, but fiscal-year operating/net losses, substantial net leverage and oversized intangibles raise material risk.
Price Behavior
Key Price Behavior Insights:
- •Modest uptrend
- •Below short-term SMA
- •High intraperiod volatility
JAZZ has traded modestly higher over the last month but is slightly below its short-term average, sitting nearer support than recent resistance and showing elevated short-term volatility that favors cautious sizing.
Rapid swing from ~ $172 to ~$197 within a few sessions indicating elevated short-term volatility
Sentiment & News
Key News Insights:
- •Record revenue
- •Oxybate strength
- •Oncology catalysts
Jazz delivered stronger-than-expected Q4 and 2025 results with record $4.3B revenue, raised 2026 guidance driven by Xywav/Epidiolex and Modeyso momentum, and set near-term upside from zanidatamab oncology catalysts and international revenue exposure.
The results and guidance should support upside in the stock near term via a relief rally while upcoming oncology readouts and international sales mix will dictate longer-term re-rating
Similar Companies in Healthcare
Other companies in the same sector with AI ratings